Navigation Links
Dr. Avrum Spira receives award for advancing research on tobacco smoke's effect on lungs
Date:10/28/2013

(Boston) Avrum Spira, MD, MSc, the Alexander Graham Bell professor of medicine and chief of the division of computational biomedicine at Boston University School of Medicine, is the recipient of the Alton Ochsner Award Relating Smoking and Disease. The award will be presented to Spira today at the Opening Session of the Annual Meeting of the American College of Chest Physicians in Chicago.

This award recognizes Spira's seminal research contributions that have enhanced the understanding of the biological response of lung tissue to tobacco smoke, which can cause lung cancer and chronic obstructive lung disease (COPD). Spira has applied innovative approaches to measure gene expression in populations of lung cells damaged by tobacco toxins and was the first to define the reversibility and permanent impact of cigarette smoke on gene activity in the bronchial airway. Spira's lab has leveraged this genomic response in the airway to develop an early detection biomarker that can enable physicians to diagnose lung cancer earlier among smokers at risk for disease. This has important scientific, clinical and therapeutic implications. More recently, his group has extended this genomic approach to develop molecular biomarkers that can guide treatment decisions in COPD and identify novel therapeutic opportunities for this chronic debilitating disease.

Spira, who also is a physician in the pulmonary, critical care and allergy department at Boston Medical Center, is a graduate of Vanier College, Montreal, Canada, the McGill University Faculty of Medicine, also in Montreal, and Boston University (BU). He also is the Director of the Translational Bioinformatics Program within the Clinical Translational Science Institute of BU.

The Award is named in honor of Doctor Alton Ochsner, co-founder of the Ochsner Clinic in New Orleans. In 1939, Ochsner was the first to publish evidence relating cigarette (tobacco) smoking as the primary cause of lung cancer.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Vitamin D supplementation can decrease risk of respiratory infections in children
3. Gene linked to respiratory distress in babies
4. Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia
5. DNA damage: The dark side of respiration
6. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
7. Pro Ana and Thinspiration Sites Under Attack
8. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
9. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
10. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
11. Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology: